Executive Summary Antibody–drug conjugates (ADCs) hold tremendous promise in both scientific innovation and clinical applications, but they also present significant challenges in manufacturing. Compared to traditional biologics or small-molecule drugs, ADC production involves: biologics (antibodies) highly potent small molecules (payloads) complex conjugation chemistry As a result, ADC manufacturing and CMC (Chemistry, Manufacturing, and Controls) often become critical bottl